<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001945'>Fever</z:hpo> is frequently the only clinical sign of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in patients with chemo-induced <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In this setting, empirical administration of broad spectrum antibiotics must be rapid </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this work was to compare, for the first time, cefpirome (CPO) and <z:chebi fb="0" ids="8232">piperacillin</z:chebi>-tazobactam (PT) in a large randomized trial </plain></SENT>
<SENT sid="3" pm="."><plain>Two hundred-eight febrile neutropenic episodes (FNE) (&gt; or = 38.5 degrees C and ANC &lt; or = 0.5 giga/l) were treated by randomization, as first line therapy, using either CPO 2 g x 2/day (105 cases) or PT 4 g x 3/day (103 cases), alone (CPO: 15/PT: 15), or plus <z:chebi fb="0" ids="47779">aminoglycoside</z:chebi> (165 cases, CPO: 82/PT: 83) or <z:chebi fb="1" ids="23765">quinolone</z:chebi> (CPO: 2/PT: 2) </plain></SENT>
<SENT sid="4" pm="."><plain>There were 131 men and 77 women aged between 17 and 83 years (median: 49) who received chemotherapy (n = 160) or allogeneic (n = 10) or autologous (n = 38) stem cell transplantations </plain></SENT>
<SENT sid="5" pm="."><plain>Underlying diseases were: <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (n = 131), <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 33), <z:mp ids='MP_0009440'>myeloma</z:mp> (n = 16), <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> (n = 8), <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> (n = 9), <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005526'>lymphoid leukemia</z:hpo> (n = 5), <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (n = 3), <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (n = 3) </plain></SENT>
<SENT sid="6" pm="."><plain>Distribution of age, <z:hpo ids='HP_0001875'>neutropenia</z:hpo> duration (median: 17 days), underlying disease, and protocol therapy duration (median: 11 days) was comparable in both arms </plain></SENT>
<SENT sid="7" pm="."><plain>A microbiologically documented <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (<z:chebi fb="5" ids="53218">MDI</z:chebi>) was evidenced in 57 cases (27%) </plain></SENT>
<SENT sid="8" pm="."><plain>Bacteria were isolated from blood cultures in 54 cases (<z:mp ids='MP_0001796'>Gram positive</z:mp>: 32 cases) </plain></SENT>
<SENT sid="9" pm="."><plain>Their in vitro susceptibility rates to CPO and PT were not different </plain></SENT>
<SENT sid="10" pm="."><plain>Two days after antibiotics initiation, clinical (<z:hpo ids='HP_0001945'>fever</z:hpo> disappearance) and microbiological (culture negativation) success rates (SR) were 62% for CPO versus 61% for PT and 50% versus 55% respectively in case of <z:chebi fb="5" ids="53218">MDI</z:chebi> (p = 0.89) </plain></SENT>
<SENT sid="11" pm="."><plain>Two <z:hpo ids='HP_0011420'>deaths</z:hpo> and 77 failures were registered </plain></SENT>
<SENT sid="12" pm="."><plain>At the end of protocol, SR (no antibiotic change/absence of <z:e sem="disease" ids="C0038826" disease_type="Disease or Syndrome" abbrv="">superinfection</z:e>) was 59% with CPO versus 50% with PT (p = 0.27) and 53% versus 40% respectively in the 151 cases with <z:hpo ids='HP_0001875'>neutropenia</z:hpo> &gt; or = 10 days (p = 0.17) </plain></SENT>
<SENT sid="13" pm="."><plain>The occurrence of side effects was similar in both arms </plain></SENT>
<SENT sid="14" pm="."><plain>In our hands, the efficacy of CPO and PT was comparable for treating FNE </plain></SENT>
</text></document>